Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
Molecular Oncology, BC Cancer Agency, Vancouver, Canada.
BMC Biol. 2020 Oct 28;18(1):154. doi: 10.1186/s12915-020-00895-0.
Aberrations in Capicua (CIC) have recently been implicated as a negative prognostic factor in a multitude of cancer types through the derepression of targets downstream of the mitogen-activated protein kinase (MAPK) signaling cascade, such as oncogenic E26 transformation-specific (ETS) transcription factors. The Ataxin-family protein ATXN1L has previously been reported to interact with CIC in both developmental and disease contexts to facilitate the repression of CIC target genes and promote the post-translational stability of CIC. However, little is known about the mechanisms at the base of ATXN1L-mediated CIC post-translational stability.
Functional in vitro studies utilizing ATXN1L human cell lines revealed that loss of ATXN1L leads to the accumulation of polyubiquitinated CIC protein, promoting its degradation through the proteasome. Although transcriptomic signatures of ATXN1L cell lines indicated upregulation of the mitogen-activated protein kinase pathway, ERK activity was found to contribute to CIC function but not stability. Degradation of CIC protein following loss of ATXN1L was instead observed to be mediated by the E3 ubiquitin ligase TRIM25 which was further validated using glioma-derived cell lines and the TCGA breast carcinoma and liver hepatocellular carcinoma cohorts.
The post-translational regulation of CIC through ATXN1L and TRIM25 independent of ERK activity suggests that the regulation of CIC stability and function is more intricate than previously appreciated and involves several independent pathways. As CIC status has become a prognostic factor in several cancer types, further knowledge into the mechanisms which govern CIC stability and function may prove useful for future therapeutic approaches.
最近,Capicua(CIC)的异常被认为是多种癌症类型的负预后因素,这是通过去抑制丝裂原活化蛋白激酶(MAPK)信号级联下游的靶标,如致癌 E26 转化特异性(ETS)转录因子来实现的。Ataxin 家族蛋白 ATXN1L 之前已被报道在发育和疾病环境中与 CIC 相互作用,以促进 CIC 靶基因的抑制和 CIC 的翻译后稳定性。然而,关于 ATXN1L 介导的 CIC 翻译后稳定性的基础机制知之甚少。
利用 ATXN1L 人细胞系进行的功能体外研究表明,ATXN1L 的缺失会导致多聚泛素化 CIC 蛋白的积累,通过蛋白酶体促进其降解。尽管 ATXN1L 细胞系的转录组特征表明丝裂原活化蛋白激酶途径的上调,但发现 ERK 活性有助于 CIC 的功能而不是稳定性。相反,在失去 ATXN1L 后,CIC 蛋白的降解被观察到是由 E3 泛素连接酶 TRIM25 介导的,这在胶质瘤衍生的细胞系以及 TCGA 乳腺癌和肝肝癌队列中得到了进一步验证。
通过 ATXN1L 和 TRIM25 对 CIC 的翻译后调节独立于 ERK 活性表明,CIC 稳定性和功能的调节比以前认为的更为复杂,涉及几个独立的途径。由于 CIC 状态已成为几种癌症类型的预后因素,进一步了解控制 CIC 稳定性和功能的机制可能对未来的治疗方法有用。